戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ction and identified unique targets for ZIKV serodiagnostics.
2 potential virulence factors and as candidate serodiagnostic and immunoprotective reagents.
3 ith disease severity and delineate promising serodiagnostic and virus neutralization targets.
4 -including improved peripheral blood and CSF serodiagnostics-and much has been learned about the inte
5 ecombinant RVFV nucleoprotein (N) for use as serodiagnostic antigen in an indirect enzyme-linked immu
6 in microarray data analysis is identifying a serodiagnostic antigen set that can reliably detect patt
7 therefore a significantly improved source of serodiagnostic antigens compared to the traditional sour
8 the rP43 and rP28 are sensitive and reliable serodiagnostic antigens for E. canis infections.
9 reviously shown to be sensitive and specific serodiagnostic antigens for HME and HGE, respectively, c
10 responses against some of the same potential serodiagnostic antigens reported previously, as well as
11                               Five potential serodiagnostic antigens were evaluated on immunostrips,
12                             About 72% of the serodiagnostic antigens were within the top 25% of the r
13  and population-specific basis, can identify serodiagnostic antigens, and contribute to a more detail
14 d the responses against additional potential serodiagnostic antigens.
15  suitability of the these 90-kDa proteins as serodiagnostic antigens.
16 s of B. miyamotoi proteins to identify novel serodiagnostic antigens.
17                                    While our serodiagnostic application focuses on SARS-CoV-2, the sa
18 B1 lipoproteins could be the basis for a new serodiagnostic assay for Lyme disease.
19                        Developing a reliable serodiagnostic assay is essential for the clinical manag
20  Taenia solium, has been the "gold standard" serodiagnostic assay since it was first described in 198
21 y antigens that might complement r38kDa in a serodiagnostic assay.
22 igens with reduced cross-reactivity in these serodiagnostic assays and others should lead to more acc
23 ngi has hampered the development of specific serodiagnostic assays for histoplasmosis.
24     These findings might guide the design of serodiagnostic assays, prognostic algorithms, therapeuti
25  degree of cross-reactivity observed in most serodiagnostic assays.
26 otein correlated with elevated titers to the serodiagnostic complement fixation antigen of C. immitis
27 surveillance questionnaires and standardized serodiagnostic criteria.
28 es, and this may require revision of current serodiagnostic criteria.
29                             To determine the serodiagnostic discriminatory ability of the antigens wi
30 ntical to that of the native protein and had serodiagnostic efficacy comparable to those of the comme
31                           HIV-Selectest is a serodiagnostic enzyme immunoassay (EIA), containing p6 a
32             Computational methods to predict serodiagnostic epitopes that are specific for the pathog
33 ential candidate proteins for developing new serodiagnostics for African trypanosomiasis.
34                                      Current serodiagnostics for Lyme disease lack sensitivity during
35 the recombinant protein may be useful in the serodiagnostic identification of A. fumigatus infections
36  not the 19- and 60-kDa antigens observed on serodiagnostic immunoblots.
37 ex of Epstein-Barr virus (EBV), an important serodiagnostic marker of infection with the virus, consi
38 mydia CFT, which is the most widely accepted serodiagnostic method for chlamydial infections in anima
39                        We then evaluated its serodiagnostic performance in comparison to that of a fi
40 5C, MPT32, and a 88-kDa protein) have strong serodiagnostic potential.
41 and preclinical tuberculosis and to identify serodiagnostic proteins for the spectrum of bacillary bu
42                    When tested by the Iatron serodiagnostic reagent kit (Iatron Laboratories, Inc.),
43  they are logical candidates for vaccine and serodiagnostic reagents.
44 mptomatic subjects with negative mRNA and/or serodiagnostic results.
45 ere is an urgent need for development of new serodiagnostic strategies for leptospirosis, an emerging
46 ntify epitopes of alpha-actinin as candidate serodiagnostic targets and suggest strongly that a highl
47 ression as well as define key protective and serodiagnostic targets.
48 uorescent-antibody assays (IFAs), a reliable serodiagnostic test for canine bartonelloses is of clini
49 n of borreliacidal antibodies is an accurate serodiagnostic test for confirmation of Lyme disease in
50 for the inclusion of rCFP-10 in a polyvalent serodiagnostic test for detection of active TB infection
51 urgdorferi isolate 50772, is also a reliable serodiagnostic test for detection of Lyme disease in dog
52 can be used to devise a simple peptide-based serodiagnostic test for TB.
53          There is a need for a point-of-care serodiagnostic test for women and men for sexually trans
54 nclusion of recombinant MTB48 in a prototype serodiagnostic test increases assay sensitivity for M. t
55 argeted PCR assay and an radaA antigen-based serodiagnostic test may be useful for differential diagn
56                   Development of an accurate serodiagnostic test requires a detailed understanding of
57                                         This serodiagnostic test was validated through a hyperimmuniz
58                      Importantly, this novel serodiagnostic test would be useful independent of prior
59   Comparison of the P37 EIA with the current serodiagnostic test, a bacterial lysate EIA, revealed re
60 utination assay (IHA) is used as a reference serodiagnostic test; however, it has low specificity in
61                         Current B. miyamotoi serodiagnostic testing depends on reactivity against Glp
62                                     The 1994 serodiagnostic testing guidelines predated a full unders
63 al patient sera presented here suggests that serodiagnostic tests based on the subset of antigens rec
64  that could form the basis of novel antibody serodiagnostic tests for human liver fluke infection and
65 y presents a challenge to the development of serodiagnostic tests for other intracellular pathogens t
66  encephalitis virus (JEV) are widely used as serodiagnostic tests for presumptive confirmation of vir
67  compared the performance of European and US serodiagnostic tests, including newer-generation assays
68 nt an urgent need for sensitive and specific serodiagnostic tests, particularly for pregnant women in
69 mphasize the need for sensitive and specific serodiagnostic tests.
70 uld aid the design of Lig-based vaccines and serodiagnostic tests.
71  or positive reactivities with more specific serodiagnostic tests.
72 -kDa antigen, an immunodominant antigen with serodiagnostic value, which has been previously cloned a